baber/WOPTO huggingface dataset:
Patent CA-2367808-A1 (CA)
Title: Procede de fabrication d'une piece en silicone destinee a etre collee et ensemble autocollant fabrique selon le procede
Inventor: LABILLE CHRISTOPHE
IPC: C09J7/38
Filed: 2000-03-17
Abstract: L'invention concerne les pièces moulées, en silicone, destinées à être collées sur un support. L'ensemble autocollant comporte un empilement avec, successivement, une pièce à coller en silicone (R), une couche (Cs) d'un adhésif à base de silicone, une feuille intermédiaire (Fi), une couche (Ce) d'un adhésif ordinaire et une feuille de protection (Fp). L'ensemble est obtenu en introduisant les feuilles (Fi, Fp) avec leurs couches de colle (Cs, Ce) dans un moule (M) puis en injectant de la résine au silicone dans le moule et en laissant polymériser. Application à toutes les pièces moulées, en silicone, montées par collage pour constituer des joints d'étanchéité, des joints de blocage, des amortisseurs, des butées.
Patent CA-2368544-A1 (CA)
Inventor: JAMES BRIAN G
IPC: H04N1/407
Filed: 2000-04-10
Abstract: Apparatus is provided for enhancing a digital image without distortion of the color. A digital format (13) contains an image. A processor (14) implements a method for extracting color dot information from the digital format and enhancing the image while varying the effective light gathering power. The image enhancement is performed in RGB color space and comprises determining the maximum strength of the R, G, and B of each dot's RGB triplet and similarly for all dots. The dot maximums are scaled through a scaling function which is constrained in domain and range to the system's dynamic range. The corresponding scaling factor that is applied to a dot maximum is also applied to each of R, G and B in the triplet. Preferably, a continuous scaling function is provided which smoothly approaches the minimum and maximum of the system's dynamic range for providing an aesthetically pleasing enhancement while maintaining true color In a forensic embodiment, a portion of the image can be selected in RGB color space and normalized to substantially the entire dynamic range, thereby emphasizing the area of interest, all without affecting the ratios of R,G and B for maintaining true color.
Patent CA-2369376-A1 (CA)
Title: Procedes, formulations pharmaceutiques et kits d'identification de sujets risquant de developper un cancer et de prevention du cancer chez les sujets a risque
Inventor: NEELY CONSTANCE F
IPC: A61K48/00
Filed: 2000-05-12
Abstract: Dans cette invention, on peut identifier les sujets risquant de développer un cancer en prélevant des échantillons ou des cellules diagnostiques sur ces sujets et en déterminant ensuite une mesure de cytotoxicité des cellules, la mesure de cytotoxicité étant en corrélation négative avec le risque de développer un cancer. En outre, on peut prévenir le développement du cancer chez un sujet déterminé comme risquant de développer un cancer en lui administrant des agents d'amorçage et d'activation, et en augmentant l'expression des récepteurs d'adénosine A¿1? dans ses cellules, en augmentant l'affinité de ses cellules pour les ligands des récepteurs d'adénosine A¿1?. Par ailleurs, les méthodes préventives et diagnostiques de cette invention peuvent être réalisées avec des kits et des formulations liposomiques pharmaceutiques.
Patent CA-2372567-A1 (CA)
Inventor: DUGAR SUNDEEP
IPC: A61P25/28
Filed: 2000-05-19
Abstract: The invention is directed to methods to inhibit p38-.alpha. kinase using compounds of formula (1), and the pharmaceutically acceptable salts thereof,  or a pharmaceutical composition thereof, wherein (a) represents a single or double bond; one Z2 is CA or CR8A and the other is CR1, CR12, NR6 or N where in each R1, R6 and R8 is independently hydrogen or noninterfering substituent; A is -Wi-COXjY wherein Y is COR2 or an isostere thereof and R2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6.ANG., and eac h of i and j is independently 0 or 1; Z3 is NR7 or O; each R3 is independently  a noninterfering substituent; n is 0-3; each of L1 and L2 is a linker; each R4  is independently a noninterfering substituent; m is 0-4; Z1 is CR5 or N wherein R5 is hydrogen or a noninterfering substituent; each of l and k is a n integer from 0-2 wherein the sum of l and k is 0-3; Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering  substituents can form a fused ring; and the distance between the atom of Ar linked to L2 and the center of the .alpha. ring is 4.5-24.ANG..
Patent CA-2373178-A1 (CA)
Title: The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
Inventor: DE JUAN EUGENE JR
IPC: A61P27/02
Filed: 2000-05-05
Abstract: The present invention is directed to a method for the prophylactic and therapeutic treatment of age-related macular degeneration as well as methods  for the prophylactic and therapeutic treatment of exudative and atrophic complications of age-related macular degeneration. The methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the animal for age-related macular degeneration or an exudative or atrophic complication thereof, respectively, prophylactically or therapeutically. The present invention further provides a method for the prophylactic and therapeutic treatment of degeneration of the retina, a meth od for the prophylactic and therapeutic treatment of degeneration of the choroi d, and a method for the prophylactic and therapeutic treatment of thickening of  Bruch's membrane. These methods involve the administration of an inhibitor o f the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the macula, retina, choroid or Bruch's membrane, respectively, prophylactically or therapeutically. The inhibitor of the protein tyrosine kinase pathway is preferably genistein or an analogue or prodrug thereof ora pharmaceutically acceptable salt of any of the foregoing.
Patent CA-2374359-A1 (CA)
Inventor: HERRON THOMAS G
IPC: H01M8/04
Filed: 2000-09-21
Abstract: A system and method for controlling a fuel processing system (10) is disclosed. The control system (26) automates the operation of a fuel processing system by monitoring operating parameters via communication pathways (62) and automatically controlling the operation of the system in response to the monitored parameters, predefined subroutines and/or inputs from a user interface (58).
Patent CA-2376382-A1 (CA)
Inventor: SATO TAKA-AKI
IPC: G01N33/68
Filed: 2000-06-07
Abstract: L'invention concerne une molécule d'un acide nucléique isolé codant pour un polypeptide capable de lier un récepteur de p75¿NTR? et une version purifiée dudit polypeptide capable de lier un récepteur de p75¿NTR?. Cette invention se rapporte à un procédé pour produire un polypeptide purifié capable de lier un récepteur de p75¿NTR?, ainsi qu'à un oligonucléotide antisens comportant une séquence d'acide nucléique capable de s'hybrider spécifiquement à une molécule d'ARNm codant le polypeptide ci-décrit. Elle décrit un procédé pour produire un polypeptide capable de lier un récepteur de p75¿NTR? à un vecteur approprié, ainsi qu'un procédé pour provoquer l'apoptose, un procédé pour déterminer les effets physiologiques, un procédé pour identifier un composé provoquant ou inhibant l'apoptose, un procédé de criblage de bibliothèques d'ADN à la recherche de ce polypeptide, un procédé pour déclencher l'activité de caspase-2 et de caspase-3 pour cliver la poly (ADP-ribose) polymérase et fragmenter l'ADN nucléaire dans une cellule, un procédé pour inhiber l'activation de NF-kB dans une cellule, un procédé pour détecter une maladie neurodégénérative, un procédé pour produire la protéine humaine isolée HGR74 sous la forme d'un vecteur approprié, une composition pharmaceutique comprenant un polypeptide purifié capable de lier un récepteur de p75¿NTR? et un excipient pharmaceutiquement acceptable et, enfin, un procédé pour identifier un composé qui est un inhibiteur d'apoptose.
Patent CA-2376645-A1 (CA)
Inventor: PRESTON JOHN CLEMENT
IPC: E04C3/04
Filed: 2000-01-24
Abstract: A fabricated structural component for skeletal framework of structures, havi ng five substantially planar faces corresponding to five faces of an elongated rectangular prism, namely a front face, two side faces and two end faces, th e component comprising two elongate rolled steel angle elements (10), and a plurality of discrete spacers (13, 14) extending between the angle elements,  and end elements (16). Each flange of the angle element (10) is pierced by a  plurality of equi-distanced fastener clearance holes (15), and the end elements (16) are pierced by two fastener clearance holes.
Patent CA-2376859-A1 (CA)
Inventor: CABRAL-LILLY DONNA
IPC: C07K5/097
Filed: 2000-06-13
Abstract: Cette invention se rapporte à des conjugués peptides-lipides qui sont incorporés dans des liposomes, afin de déstabiliser sélectivement les liposomes à proximité de cellules cibles sécrétant de la peptidase et, ainsi, acheminer les liposomes à proximité des cellules cibles ou directement dans lesdites cellules. Les liposomes peuvent par conséquent être utilisés pour traiter des mammifères souffrant de maladies, troubles ou états, tels que tumeurs, infections microbiennes et inflammations, se caractérisant par la présence de cellules sécrétant de la peptidase.
Patent CA-2379741-A1 (CA)
Title: Instant messaging using a wireless interface
Inventor: AVINO MARGARET
IPC: H04M11/00
Filed: 2002-03-28
Abstract: The present invention allows telephony users and on-line users to communicate with one another using an instant messaging (IM) service. The on-line user will provide and receive textual messages, wherein the telephony user will provide and receive corresponding audible messages. These messages may convey emotion using associated emotional indicia, such as emoticons, or other emotional indicia, including the use of capitalization, emphasis, and the like. Emotional indicia provided in the text messages from the on-line user are audibly conveyed to the telephony user.      Similarly, emotional indicia provided by the telephony user in the form of actual emotions or commands are provided in text to the on-line user.
Patent CA-2383248-A1 (CA)
Title: Apparatus for electrically preparing injectable substances
Inventor: ORTON KEVIN
IPC: B65D53/04
Filed: 2000-09-21
Abstract: A container has at least one wall. A reservoir is defined within the wall. The reservoir can be sealed. At least one electrode ex-tends at least partially into the sealed reservoir. An electrical contact element is connected to the electrode to facilitate electrically coupling the signal generator or other electrical supply to the electrode.
Patent CA-2383444-A1 (CA)
Title: Positive indication system for well annulus cement displacement
Inventor: JOHNSON JOHN J
IPC: E21B43/10
Filed: 2002-04-24
Abstract: An annulus collar around a well production tube is cast in cement by a procedure that axially delineates the collar between two expandable well packers in the production tube string. Between the packers are a pair of cementing valves. An ingress valve is most proximate to the lower packer whereas an egress valve is most proximate to the upper packer. Additionally, the egress valve is modified to enclose the egress valve with a screen having mesh or slot openings that correspond with a screen plugging material that is mixed with the cement.
Patent CA-2384597-A1 (CA)
Title: Improved retractable needle single use safety syringe
Inventor: MAHURKAR SAKHARAM D
IPC: A61M5/31
Filed: 2002-05-02
Abstract: A safety syringe assembly includes an elongated, generally cylindrical barrel having a hollow interior forming a hollow nozzle located at a distal end of the barrel and opening into the interior of the barrel. A plunger is slidably mounted in the barrel and has a longitudinal open channel. A needle holder mounts a needle at a distal end thereof and is slidably mounted in the longitudinal open channel of the plunger for movement between an advanced position in which the needle on the distal end of the needle holder projects from a distal end of the nozzle, and a retracted position in which the needle is retracted within the barrel. A compression spring is mounted inside of the barrel, and a spring retainer element has a spring support portion extending from the interiorly of the barrel to a portion for mounted within the barrel and supporting a distal end portion of the spring against expansion. The spring urges the needle holder toward its retracted position. A latch has a closed position in which the needle holder is latched relative to the barrel to hold the needle holder in its advanced position against the urging of the spring, and an open position in which the needle holder is unlatched relative to the barrel to allow the spring to expand in a proximal direction to move the needle holder to its retracted position.
Patent CA-2385262-A1 (CA)
Title: Nucleoside derivatives with photolabile protecting groups
Inventor: PFLEIDERER WOLFGANG
IPC: C07H19/16
Filed: 2000-10-10
Abstract: The invention relates to nucleoside derivatives with photolabile protecting groups of general formula (I), where R1 = H, F, Cl, Br, I, NO2; R2 = H, CN, where R1 and R2 are not simultaneously H; R3 = H, 1 - 4 C alkyl, phenyl; R4 = H or a conventional functional group for the synthesis of oligonucleotides; R5 = H, OH, halogen or XR6, where X = O or S and R6 = a conventional nucleotide  protecting group; B = adenine, cytosine, guanine, thymine, uracil, 2,6- diaminopurin-9-yl, hypoxanthin-9-yl, 5-methylcytosin-1-yl, 5-amino-4- imidazolcarboxamid-1-yl or 5-amino-4-imidazolcarboxamid-3-yl, where, if B = adenine, cytosine or guanine the primary amine functionality, optionally, carries a permanent protecting group. Furthermore, these derivatives may be used for the light-controlled synthesis of oligonucleotides on a DNA chip.</ SDOAB>
Patent CA-2385920-A1 (CA)
Inventor: DOCTER EELCO
IPC: C12Q1/6883
Filed: 2000-09-19
Abstract: A diagnostic method for the detection of the 5T, 7T and 9T alleles in intron  (8) of the human CFTR gene which method comprises contacting a test sample o f nucleic acid from an individual with a multiplex of diagnostic primers comprising (i) 5T variant primer 5'(N)nAAAGAC3', (ii) 7T variant primer 5'(N*)n*(N)nAAAAGC3' and (iii) 9T variant primer 5'(N*)n*(N)nAAAATC3', where in N represents additional nucleotides which base pair with the corresponding genomic sequence in the respective allele and n is an integer between 10 and  30 and N* represents additional non-homologous nucleotides which do not base  pair with the corresponding genomic sequence in the respective allele and n*  is an integer between 5 and 60, in the presence of appropriate nucleotide triphosphates and an agent for polymerisation, such that a diagnostic primer  is extended only when the corresponding allelic variant is present in the sample; and detecting the presence or absence of the allelic variant by reference to the presence or absence of a diagnostic primer extension produc t.
Patent CA-2386620-A1 (CA)
Title: Shutter mechanism for a latch
Inventor: LAI EUGENE
IPC: E05B17/00
Filed: 2000-05-05
Abstract: A latch (10) has a housing (12) defining a mouth (14), a ratchet (18) pivotally mounted to cooperate with the mouth to move between a latched condition and an unlatched condition, a pivotally mounted pawl (30) engaging the ratchet (18) and rotatable to selectively engage the ratchet (18) to retain the ratchet (18) in the latched condition, and a release ]ever (40) pivotally mounted and pivotally connected to the pawl (30) for effecting movement of the pawl to disengage the ratchet.  A shutter (50) is slidably mounted to move between a cover condition positioned to cover the ratchet (18) and an open condition allowing relative movement of a striker to latch and unlatch with the ratchet (18). The shutter (50) is biased to the cover condition.
Patent CA-2387734-A1 (CA)
Title: Geranyl diphosphate synthase large subunit, and methods of use
Inventor: WILDUNG MARK R
IPC: C12N15/82
Filed: 2000-10-16
Abstract: A cDNA encoding geranyl diphosphate synthase large subunit from peppermint h as been isolated and sequenced, and the corresponding amino acid sequence has been determined. Replicable recombinant cloning vehicles are provided which code for geranyl disphosphate synthase large subunit. In another aspect, modified host cells are provided that have been transformed, transfected, infected and/or injected with a recombinant cloning vehicle and/or DNA sequence encoding geranyl diphosphate synthase protein comprising an isolate d, recombinant geranyl diphosphate synthaxe large subunit. In yet another aspec t, the present invention provides isolated, recombinant geranyl diphosphate synthase large subunit protein and an isolated, recombinant geranyl diphosphate synthase small subunit protein. Thus, systems and methods are provided for the recombinant expression of geranyl diphosphate synthase.</SD OAB>
Patent CA-2388196-A1 (CA)
Inventor: PAULEY SUZANNE M
IPC: A61F13/20
Filed: 2000-10-06
Abstract: There is provided a tampon pledget (5) that expands without the aid of moisture or menses. The tampon pledget has a plurality of high resiliency, non-absorbent materials and a plurality of absorbent materials. The tampon pledget has improved comfort as compared to conventional fully compressed tampon pledgets. The tampon pledget preferably has all of its non-absorbent and absorbent materials enclosed in a coverstock (12). The coverstock (12) may be inverted or turned inside out, prior to filling the coverstock with a plurality of non-absorbent and absorbent materials.
Patent CA-2389099-A1 (CA)
Inventor: RAMAN KASHYAP
IPC: H01S5/12
Filed: 2002-06-17
Abstract: This invention relates to an external cavity laser made with a semiconductor light emitting source coupled to a grating in a multimode fibre. Applications include enhanced stability for high output-power operation for pumping high-power fibre lasers and amplifiers.
Patent CA-2389236-A1 (CA)
Inventor: BERNER BRET
IPC: A61K31/047
Filed: 2000-10-30
Abstract: L'invention concerne des médicaments destinés à être absorbés dans l'estomac ou la partie supérieure du tractus intestinal, par le biais de systèmes d'administration orale, en combinaison avec différentes substances dont on a découvert qu'elles étaient de puissants agents déclencheurs du mode par ingestion. En déclenchant ce mode, lesdits agents conduisent l'estomac à prolonger la rétention du système d'administration des médicaments, lequel a une taille suffisamment importante pour une rétention dans l'estomac en mode par ingestion ou subit une expansion pour atteindre cette taille au moment de l'ingestion. Les agents déclencheurs du mode par ingestion comprennent les composés suivants et leurs sels: glycine et glycylglycine, xylitol et alcools de sucre connexes, sodium et autres docusates métalliques, .szlig.-casomorphines, acide a-lipoïque et acides à structure similaire, 2,2-diaryle-4-(4'-aryle-4'-hydroxypiperidino)butyramides, arginine, Trp-Trp, halogénures d'alkylpyridinium, acides dihydroxybenzoïques, et puissants édulcorants du type aspartame, acide aspartique, acésulfame, et stévioside.
Patent CA-2389420-A1 (CA)
Inventor: DOUGHERTY WILLIAM FRANCIS MICH
IPC: A63H17/00
Filed: 2002-06-06
Abstract: A sound activated toy vehicle includes a body, a chassis, and a motor. The chassis accommodates the body and has at least a front wheel and a rear wheel. The motor is drivingly connected to at least one of the front wheel and the rear wheel. The toy vehicle also includes a sound transducer configured to generate an electrical signal in response to detected sound. The toy vehicle also includes a controller having an input electrically connected to the sound transducer and an output electrically connected to the motor. The controller changes the output to the motor when the electrical signal is received by the input from the sound transducer. The toy vehicle also includes a vehicle accessory having an exterior portion. The vehicle accessory is mounted for movement between a first position and a second position by mechanical power from the motor.
Patent CA-2389881-A1 (CA)
Inventor: ROSZAK SEBASTIEN
IPC: B64D27/26
Filed: 2002-06-10
Abstract: Device for recovering forces generated by an aircraft engine.  The device comprises an engine strut (10), capable of being fixed to a wing or a fuselage of an aircraft, and an attachment device (12) fixed to the engine strut (10) and on which the engine is mounted. An intermediate fitting (24) of large dimensions, capable of recovering exceptionally high forces is fixed to several strut fittings (30) independent from each other, for example by bolts (28), across a lower spar (14) of the engine strut (10).
Patent CA-2389977-A1 (CA)
Inventor: BLAU HANNE ANNA KATHERINA
IPC: C07C311/48
Filed: 2000-12-18
Abstract: L'invention concerne une méthode de préparation d'un monomère d'imide de fluorosulfonyle possédant une structure représentée par la formule (IV), dans laquelle X est F ou un perfluoroalkyle possédant de 1 à 4 carbones éventuellement substitués par de l'oxygène d'éther, M est un métal alcalin ou un métal alcalin terreux lorsque y est respectivement 1 ou 2, R est un aryle, un aryle fluoré, ou XCF¿2?- lorsque X est H, halogène, alkyle fluoré ou non fluoré linéaire ou cyclique possédant de 1 à 10 carbones éventuellement substitués par un ou plusieurs oxygènes d'éther. Ces monomères sont utilisés pour former des ionomères utilisés dans des applications électrochimiques telles que les batteries, les cellules électrochimiques, les cellules électrolytiques, des membranes d'échange d'ions, des capteurs, des condensateurs électrochimiques, des catalyseurs fortement acides, et des électrodes modifiées.
Patent CA-2391370-A1 (CA)
Title: Method of cryopreserving selected sperm cells
Inventor: SCHENK JOHN
IPC: C12N5/06
Filed: 2000-11-22
Abstract: The present invention provides a method of cryopreserving sperm that have been selected for a specific characteristic.  In a preferred embodiment, the method is employed to freeze sex-selected sperm. Although the cryopreservation method of the invention can be used to freeze sperm selected by any number of selection methods, selection using flow cytometry is preferred.  The present invention also provides a frozen sperm sample that has been selected for a particular characteristic, such as sex-type. In preferred embodiments, the frozen sperm sample includes mammalian sperm, such as, for example, human, bovine, equine, porcine, ovine, elk, or bison sperm. The frozen selected sperm sample can be used in a variety of applications. In particular, the sample can be thawed and used for fertilization. Accordingly, the invention also includes a method of using the frozen selected sperm sample for artificial insemination or in vitro fertilization.
Patent CA-2391404-A1 (CA)
Inventor: MOLLER BIRGER LINDBERG
IPC: C12Q1/68
Filed: 2000-11-29
Abstract: The present invention provides DNA molecules coding for a UDP-glucose:aglycon-glucosyltransferase conjugating cyanohydrins, terpenoids, phenylderivatives or hexanolderivatives to glucose. Transgenic expression of corresponding genes in plants can be used to influence the biosynthesis of the corresponding glucosides.